[HTML][HTML] Re-emergence of interferon-α in the treatment of chronic myeloid leukemia
M Talpaz, R Hehlmann, A Quintas-Cardama, J Mercer… - Leukemia, 2013 - nature.com
Abstract Treatment for chronic myeloid leukemia (CML) has evolved from chemotherapy
(busulfan, hydroxyurea) to interferon-α (IFNα), and finally to tyrosine kinase inhibitors such …
(busulfan, hydroxyurea) to interferon-α (IFNα), and finally to tyrosine kinase inhibitors such …
Re-emergence of interferon-α in the treatment of chronic myeloid leukemia
M Talpaz, R Hehlmann, A Quintás-Cardama… - …, 2013 - augusta.elsevierpure.com
Abstract Treatment for chronic myeloid leukemia (CML) has evolved from chemotherapy
(busulfan, hydroxyurea) to interferon-α (IFNα), and finally to tyrosine kinase inhibitors such …
(busulfan, hydroxyurea) to interferon-α (IFNα), and finally to tyrosine kinase inhibitors such …
Re-emergence of interferon-α in the treatment of chronic myeloid leukemia.
M Talpaz, R Hehlmann… - Leukemia …, 2013 - search.ebscohost.com
Abstract Treatment for chronic myeloid leukemia (CML) has evolved from chemotherapy
(busulfan, hydroxyurea) to interferon-α (IFNα), and finally to tyrosine kinase inhibitors such …
(busulfan, hydroxyurea) to interferon-α (IFNα), and finally to tyrosine kinase inhibitors such …
[引用][C] Re-emergence of interferon-α in the treatment of chronic myeloid leukemia
M Talpaz, R Hehlmann, A Quintás-Cardama, J Mercer… - Leukemia, 2012 - cir.nii.ac.jp
Re-emergence of interferon-α in the treatment of chronic myeloid leukemia | CiNii Research
CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …
CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …
[PDF][PDF] Re-emergence of interferon-α in the treatment of chronic myeloid leukemia
M Talpaz, R Hehlmann, A Quintás-Cardama… - Leukemia, 2013 - scienceopen.com
Treatment for chronic myeloid leukemia (CML) has evolved from chemotherapy (busulfan,
hydroxyurea) to interferon-α (IFNα), and finally to tyrosine kinase inhibitors such as imatinib …
hydroxyurea) to interferon-α (IFNα), and finally to tyrosine kinase inhibitors such as imatinib …
Re-emergence of interferon-α in the treatment of chronic myeloid leukemia
M Talpaz, R Hehlmann, A Quintás-Cardama… - …, 2013 - pubmed.ncbi.nlm.nih.gov
Treatment for chronic myeloid leukemia (CML) has evolved from chemotherapy (busulfan,
hydroxyurea) to interferon-α (IFNα), and finally to tyrosine kinase inhibitors such as imatinib …
hydroxyurea) to interferon-α (IFNα), and finally to tyrosine kinase inhibitors such as imatinib …
[HTML][HTML] Re-emergence of interferon-α in the treatment of chronic myeloid leukemia
M Talpaz, R Hehlmann, A Quintás-Cardama, J Mercer… - Leukemia, 2013 - ncbi.nlm.nih.gov
Abstract Treatment for chronic myeloid leukemia (CML) has evolved from chemotherapy
(busulfan, hydroxyurea) to interferon-α (IFNα), and finally to tyrosine kinase inhibitors such …
(busulfan, hydroxyurea) to interferon-α (IFNα), and finally to tyrosine kinase inhibitors such …
[PDF][PDF] Re-emergence of interferon-α in the treatment of chronic myeloid leukemia
M Talpaz, R Hehlmann, A Quintás-Cardama, J Mercer… - Leukemia, 2013 - cyberleninka.org
Treatment for chronic myeloid leukemia (CML) has evolved from chemotherapy (busulfan,
hydroxyurea) to interferon-α (IFNα), and finally to tyrosine kinase inhibitors such as imatinib …
hydroxyurea) to interferon-α (IFNα), and finally to tyrosine kinase inhibitors such as imatinib …
[PDF][PDF] Re-emergence of interferon-α in the treatment of chronic myeloid leukemia
M Talpaz, R Hehlmann, A Quintás-Cardama, J Mercer… - Leukemia, 2013 - Citeseer
Treatment for chronic myeloid leukemia (CML) has evolved from chemotherapy (busulfan,
hydroxyurea) to interferon-α (IFNα), and finally to tyrosine kinase inhibitors such as imatinib …
hydroxyurea) to interferon-α (IFNα), and finally to tyrosine kinase inhibitors such as imatinib …
Re-emergence of interferon-α in the treatment of chronic myeloid leukemia.
M Talpaz, R Hehlmann, A Quintás-Cardama, J Mercer… - Leukemia, 2012 - europepmc.org
Abstract Treatment for chronic myeloid leukemia (CML) has evolved from chemotherapy
(busulfan, hydroxyurea) to interferon-α (IFNα), and finally to tyrosine kinase inhibitors such …
(busulfan, hydroxyurea) to interferon-α (IFNα), and finally to tyrosine kinase inhibitors such …